Results 171 to 180 of about 33,479 (238)

Sequential tislelizumab plus bronchial arterial chemoembolization and systemic chemotherapy in advanced NSCLC with bulky tumors: efficacy and safety. [PDF]

Front Immunol
Quan Y, Liang Z, Wei Y, Li H, Zeng Y, Shen J, Su S, Liu X, Huang Z, Wang M, Luo H, Hu Y, Peng J.   +12 more
europepmc   +1 more source

Liver resection is associated with better survival than TACE for hepatocellular carcinoma modestly beyond Milan criteria: a multicenter propensity-matched analysis. [PDF]

Front Oncol
Fan X, Sun G, Meng Y, Liu X, Zhang L, Peng Y, Wang P, Qiao L, Zhu J, Chen R.   +9 more
europepmc   +1 more source

Efficacy of lenvatinib combined with sintilimab and transcatheter arterial chemoembolization in conversion therapy for unresectable hepatocellular carcinoma. [PDF]

Pak J Med Sci
Long J, Zheng J, Chen S, Ou P, Lu X.
europepmc   +1 more source

Comparative efficacy of postoperative adjuvant transcatheter arterial chemoembolization versus lenvatinib plus tislelizumab in patients with BCLC stage 0 -B hepatocellular carcinoma after radical resection. [PDF]

Front Immunol
Feng X, Ao Y, Wang L, Chen K, Tang C, Huang C.   +5 more
europepmc   +1 more source

Transarterial chemoembolization combined with PD-1 inhibitors for unresectable hepatocellular carcinoma: efficacy and hepatic safety at 4-week versus 6-week treatment intervals. [PDF]

Am J Transl Res
Tian T, Wang Y, Guo W.
europepmc   +1 more source

Local Tumor Response to Conventional Transarterial Chemoembolization following Seven-day Lenvatinib Administration. [PDF]

Interv Radiol (Higashimatsuyama)
Kageyama K, Uchida-Kobayashi S, Shinkawa H, Yamamoto A, Odagiri N, Kinoshita M, Nakano-Maebayashi M, Asano K, Fujii H, Enomoto M, Ishizawa T, Miki Y.   +11 more
europepmc   +1 more source

Prevalence of gastrointestinal side effects in hepatocellular carcinoma patients receiving sorafenib: a meta-analysis of 136 studies and 14,416 patients. [PDF]

Ther Adv Med Oncol
Arendt N, Payo-Serafín T, Kolosenko A, Kopsida M, Sjöblom M, Heindryckx F.   +5 more
europepmc   +1 more source

Efficacy and safety of transarterial chemoembolization plus donafenib with or without camrelizumab for unresectable hepatocellular carcinoma: a propensity score matching analysis. [PDF]

Front Immunol
Zhang Q, Lei Z, Qing H, Xie X.
europepmc   +1 more source

Efficacy and safety of CalliSpheres drug-eluting bead transarterial chemoembolization for unresectable gastrointestinal stromal tumor liver metastases after failure of targeted therapy: a multicenter retrospective study. [PDF]

Front Oncol
Liu S, Chen T, Yin S, Yu G, Wang Q, Li L, Zhao G, Zhang L, Zhuang B.   +8 more
europepmc   +1 more source

Drug-eluting bead transarterial chemoembolization combined with immune checkpoint inhibitors is associated with improved progression-free survival in locally advanced or metastatic sarcoma: a retrospective propensity score-matched analysis. [PDF]

Ther Adv Med Oncol
Zhou C, Li H, Qian G, Yu W, Zheng S, Shen Z, Wang Y.   +6 more
europepmc   +1 more source